The Mexico radiopharmaceuticals market is expected to witness a favorable growth during the forecast period. With the rise in investments in R&D of radiopharmaceuticals for clinical and restorative applications, the market is expected to witness significant growth. The essential radioisotopes in the radiopharmaceuticals market in Mexico are Technetium 99m, Fluorine 18, Iodine I, Gallium 68, and also others. The significant applications of radiopharmaceuticals in Mexico include cancer, cardiology, and others. In terms of type, the major radiopharmaceuticals in the Mexican market are diagnostic and therapeutic. The major customers of radiopharmaceuticals are hospitals & clinics, medical imaging centers, and others.

The development of the Mexico radiopharmaceuticals market can be attributed to factors such as a rising prevalence of cancer worldwide, technical improvements in radiopharmaceuticals, as well as using radiopharmaceuticals for medical diagnosis of specific diseases. The rising prevalence of cancer cells in Mexico as well as the increasing demand for early diagnosis of cancer cells are anticipated to be the major factors driving the development in this market. The rising preference for nuclear medicine procedures owing to its effectiveness for imaging as well as medical diagnosis is additionally expected to drive the growth of the market. In addition, the introduction of 3D printing innovation in the production of radiopharmaceuticals is anticipated to develop opportunities for new product launches during the forecast years.

On the contrary, the rigid governing regulations as well as the high cost of radiopharmaceuticals are anticipated to act as restricting factors for the market growth. Furthermore, stringent federal government regulations regarding the supply and circulation are expected to hamper the development of the market during the forecast years.

The market environment of Mexico radiopharmaceuticals is studied by using Porter’s 5 forces analysis. Threat of new participants, negotiating power of purchasers, negotiating power of distributors, threat of substitutes, and degree of competitive rivalry in the market are taken into consideration. The risk of new entrants out there is mini due to stringent guidelines associated with the manufacturing and sale of radiopharmaceuticals. In addition, the presence of many well-known players in the market also restricts the entry of new players as well as creates a competitive environment in the market. The bargaining power of purchasers in the market is moderate owing to the presence of several well-known distributors. Moreover, the vendors usually offer discount rates to customers for bulk orders, which further strengthens their power in the market.

The bargaining power of distributors is low, owing to the visibility of presence distributors. In addition, customers can conveniently switch over to a different supplier owing to the presence of several providers in the market. The threat of alternatives is low, due to the benefits of radiopharmaceuticals for diagnosis and imaging. The accessibility of alternatives such as optical imaging and magnetic vibration imaging for imaging & medical diagnosis is low. The level of competitive rivalry in the market is high due to the existence of reputable players in the industry. In addition, the introduction of new modern technologies and the substantial financial investments in R&D tasks in the sector have actually increased the number of competitors in the market.

The future trends in the Mexico radiopharmaceuticals market include the introduction of new radiopharmaceuticals, R&D in the field of imaging, and the presence of new players in the market. The use of radiopharmaceuticals in targeted therapies is expected to increase in the upcoming years. In addition, the increasing awareness about the benefits of radiopharmaceuticals is anticipated to drive the growth of the market during the forecast period.

The demand need for radiopharmaceuticals from the healthcare facilities and clinical imaging facilities is expected to boost the market growth. Furthermore, the rising technical innovations in radiopharmaceuticals is expected to create possibilities for new product launches in the market. The leading players in the Mexico radiopharmaceuticals market are focusing on launching new products in the market. They are additionally investing dramatically in R&D tasks. For instance, in March 2019, the U.S.-based radioisotope business, PETnet Solutions, released a brand-new radioisotope, Technetium 99m, in Mexico. In addition, the business has actually established solution facilities in significant cities of Mexico, which offers radiopharmaceuticals to the local healthcare facilities.

The leading companies are also concentrating on expanding their manufacturing capacity. For instance, in February 2020, the Mexican radiopharmaceuticals firm, Ergomed, announced the development of its radiopharmaceuticals.

Key companies profile in the report are Sanofi, Gammaglobulin, Grupo Angel, Promecaps SA, Radiofarm SA de CV, Micro-Innova SA de CV, Nucleomex SA de CV, Plena Pharma SA de CV, Bioenex SA de CV, Farmefluar SA de CV.

The radiopharmaceuticals market share is segmented into Radioisotope, Application, Type, End User, and region. On the basis of radioisotopes, the market is classified into Technetium-99m, Fluorine-18, Iodine I, Gallium-68, and others. On the basis of application, the market is divided into cancer, cardiology, and others. On the basis of type, the market is bifurcated into diagnostic, and therapeutic. On the basis of end user, the market is fragmented into hospitals and clinics, medical imaging centers, and others. The others segment includes diagnostic centers, and research institute.

Key Benefits For Stakeholders

Enable informed decision-making process and offer market analysis based on current market situation and estimated future trends.

Analyze the key strategies adopted by major market players in mexico radiopharmaceuticals market.

Assess and rank the top factors that are expected to affect the growth of mexico radiopharmaceuticals market.

Top Player positioning provides a clear understanding of the present position of market players.

Detailed analysis of the mexico radiopharmaceuticals market segmentation assists to determine the prevailing market opportunities.

Identify key investment pockets for various offerings in the market.

Additional benefits you will get with this purchase are:

● Quarterly Update and* (only available with a corporate license, on listed price)

● 5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.

● Free Upcoming Version on the Purchase of Five and Enterprise User License.

● 16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)

● 15% Free Customization* (in case the scope or segment of the report does not match your requirements, 15% is equivalent to 3 working days of free work, applicable once)

● Free data Pack on the Five and Enterprise User License. (Excel version of the report)

● Free Updated report if the report is 6-12 months old or older.

● 24-hour priority response*

● Free Industry updates and white papers.

Possible Customization with this report (with additional cost and timeline, please talk to the sales executive to know more)

○ Farmefluar SA de C

Scope of Mexico Radiopharmaceuticals Market Report

Report Metric	Details
Report Name	Mexico Radiopharmaceuticals Market
By Type	● Diagnostic ● Therapeutic
By End User	● Hospitals and clinics ● Medical Imaging centers ● Others
By Radioisotope	● Fluorine 18 ● Iodine I ● Gallium 68 ● Others ● Technetium 99m
By Application	● Cancer ● Cardiology ● Others ● Key Market Players ○ Sanofi ○ Gammaglobulin ○ Grupo Angel ○ Promecaps SA ○ Radiofarm SA de CV ○ Micro-Innova SA de CV ○ Nucleomex SA de CV ○ Plena Pharma SA de CV ○ Bioenex SA de CV
● New Product Development/ Product Matrix of Key Players	● Patient/epidemiology data at country, region, global level, ● Regulatory Guidelines, ● Additional company profiles with specific to client's interest, ● Additional country or region analysis- market size and forecast, ● Expanded list for Company Profiles, ● Historic market data, ● Key player details (including location, contact details, supplier/vendor network etc. in excel format), ● SWOT Analysis, Key Market Segments
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

FAQ for this report

Who are the main players in the Mexico Radiopharmaceuticals Market report?

Ans: The main players in the Mexico Radiopharmaceuticals Market are ● Patient/epidemiology data at country, region, global level, ● Regulatory Guidelines, ● Additional company profiles with specific to client's interest, ● Additional country or region analysis- market size and forecast, ● Expanded list for Company Profiles, ● Historic market data, ● Key player details (including location, contact details, supplier/vendor network etc. in excel format), ● SWOT Analysis, Key Market Segments

What are the Application segmentation covered in the Mexico Radiopharmaceuticals Market report?

Ans: The Applications covered in the Mexico Radiopharmaceuticals Market report are ● Cancer, ● Cardiology, ● Others, ● Key Market Players, ○ Sanofi, ○ Gammaglobulin, ○ Grupo Angel, ○ Promecaps SA, ○ Radiofarm SA de CV, ○ Micro-Innova SA de CV, ○ Nucleomex SA de CV, ○ Plena Pharma SA de CV, ○ Bioenex SA de CV

What are the Type segmentation covered in the Mexico Radiopharmaceuticals Market report?

Ans: The Types covered in the Mexico Radiopharmaceuticals Market report are ● Diagnostic, ● Therapeutic

What are the End User segmentation covered in the Mexico Radiopharmaceuticals Market report?

Ans: The End users covered in the Mexico Radiopharmaceuticals Market report are ● Hospitals and clinics, ● Medical Imaging centers, ● Others

CHAPTER 1: INTRODUCTION

1.1. Report Description

1.2. Key Market Segments

1.3. Key Benefits to the Stakeholders

1.4. Research Methodology

1.4.1. Primary Research

1.4.2. Secondary Research

1.4.3. Analyst Tools and Models

CHAPTER 2: EXECUTIVE SUMMARY

2.1. CXO Perspective

CHAPTER 3: MARKET OVERVIEW

3.1. Market Definition and Scope

3.2. Key Findings

3.2.1. Top Impacting Factors

3.2.2. Top Investment Pockets

3.3. Porter’s Five Forces Analysis

3.4. Market Dynamics

3.4.1. Drivers

3.4.2. Restraints

3.4.3. Opportunities

3.5. COVID-19 Impact Analysis on the market

CHAPTER 4: MEXICO RADIOPHARMACEUTICALS MARKET, BY RADIOISOTOPE

4.1. Overview

4.1.1. Market Size and Forecast, By Radioisotope

4.2. Technetium 99m

4.3. Fluorine 18

4.4. Iodine I

4.5. Gallium 68

4.6. Others

CHAPTER 5: MEXICO RADIOPHARMACEUTICALS MARKET, BY APPLICATION

5.1. Overview

5.1.1. Market Size and Forecast, By Application

5.2. Cancer

5.3. Cardiology

5.4. Others

CHAPTER 6: MEXICO RADIOPHARMACEUTICALS MARKET, BY TYPE

6.1. Overview

6.1.1. Market Size and Forecast, By Type

6.2. Diagnostic

6.3. Therapeutic

CHAPTER 7: MEXICO RADIOPHARMACEUTICALS MARKET, BY END USER

7.1. Overview

7.1.1. Market Size and Forecast, By End User

7.2. Hospitals and clinics

7.3. Medical Imaging centers

7.4. Others

CHAPTER 8: COMPETITIVE LANDSCAPE

8.1. Introduction

8.2. Top winning strategies

8.3. Product Mapping of Top 10 Player

8.4. Competitive Dashboard

8.5. Competitive Heatmap

8.6. Top player positioning, 2022

CHAPTER 9: COMPANY PROFILES

9.1. Company 1

9.1.1. Company overview

9.1.2. Key Executives

9.1.3. Company snapshot

9.1.4. Operating business segments

9.1.5. Product portfolio

9.1.6. Business performance

9.1.7. Key strategic moves and developments

9.2. Company 2

9.2.1. Company overview

9.2.2. Key Executives

9.2.3. Company snapshot

9.2.4. Operating business segments

9.2.5. Product portfolio

9.2.6. Business performance

9.2.7. Key strategic moves and developments

9.3. Company 3

9.3.1. Company overview

9.3.2. Key Executives

9.3.3. Company snapshot

9.3.4. Operating business segments

9.3.5. Product portfolio

9.3.6. Business performance

9.3.7. Key strategic moves and developments

9.4. Company 4

9.4.1. Company overview

9.4.2. Key Executives

9.4.3. Company snapshot

9.4.4. Operating business segments

9.4.5. Product portfolio

9.4.6. Business performance

9.4.7. Key strategic moves and developments

9.5. Company 5

9.5.1. Company overview

9.5.2. Key Executives

9.5.3. Company snapshot

9.5.4. Operating business segments

9.5.5. Product portfolio

9.5.6. Business performance

9.5.7. Key strategic moves and developments

9.6. Company 6

9.6.1. Company overview

9.6.2. Key Executives

9.6.3. Company snapshot

9.6.4. Operating business segments

9.6.5. Product portfolio

9.6.6. Business performance

9.6.7. Key strategic moves and developments

9.7. Company 7

9.7.1. Company overview

9.7.2. Key Executives

9.7.3. Company snapshot

9.7.4. Operating business segments

9.7.5. Product portfolio

9.7.6. Business performance

9.7.7. Key strategic moves and developments

9.8. Company 8

9.8.1. Company overview

9.8.2. Key Executives

9.8.3. Company snapshot

9.8.4. Operating business segments

9.8.5. Product portfolio

9.8.6. Business performance

9.8.7. Key strategic moves and developments

9.9. Company 9

9.9.1. Company overview

9.9.2. Key Executives

9.9.3. Company snapshot

9.9.4. Operating business segments

9.9.5. Product portfolio

9.9.6. Business performance

9.9.7. Key strategic moves and developments

9.10. Company 10

9.10.1. Company overview

9.10.2. Key Executives

9.10.3. Company snapshot

9.10.4. Operating business segments

9.10.5. Product portfolio

9.10.6. Business performance

9.10.7. Key strategic moves and development

FEATURED COMPANIES

Micro-Innova SA de CV

Nucleomex SA de CV

Plena Pharma SA de CV

Bioenex SA de CV

Farmefluar SA de CV

LIST OF TABLES

TABLE 01. MEXICO RADIOPHARMACEUTICALS MARKET, BY RADIOISOTOPE, 2022-2032 ($MILLION)

TABLE 02. MEXICO RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2022-2032 ($MILLION)

TABLE 03. MEXICO RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2032 ($MILLION)

TABLE 04. MEXICO RADIOPHARMACEUTICALS MARKET, BY END USER, 2022-2032 ($MILLION)

TABLE 05. COMPANY 1: KEY EXECUTIVES

TABLE 06. COMPANY 1: COMPANY SNAPSHOT

TABLE 07. COMPANY 1: OPERATING SEGMENTS

TABLE 08. COMPANY 1: PRODUCT PORTFOLIO

TABLE 09. COMPANY 1: KEY STRATERGIES

TABLE 10. COMPANY 2: KEY EXECUTIVES

TABLE 11. COMPANY 2: COMPANY SNAPSHOT

TABLE 12. COMPANY 2: OPERATING SEGMENTS

TABLE 13. COMPANY 2: PRODUCT PORTFOLIO

TABLE 14. COMPANY 2: KEY STRATERGIES

TABLE 15. COMPANY 3: KEY EXECUTIVES

TABLE 16. COMPANY 3: COMPANY SNAPSHOT

TABLE 17. COMPANY 3: OPERATING SEGMENTS

TABLE 18. COMPANY 3: PRODUCT PORTFOLIO

TABLE 19. COMPANY 3: KEY STRATERGIES

TABLE 20. COMPANY 4: KEY EXECUTIVES

TABLE 21. COMPANY 4: COMPANY SNAPSHOT

TABLE 22. COMPANY 4: OPERATING SEGMENTS

TABLE 23. COMPANY 4: PRODUCT PORTFOLIO

TABLE 24. COMPANY 4: KEY STRATERGIES

TABLE 25. COMPANY 5: KEY EXECUTIVES

TABLE 26. COMPANY 5: COMPANY SNAPSHOT

TABLE 27. COMPANY 5: OPERATING SEGMENTS

TABLE 28. COMPANY 5: PRODUCT PORTFOLIO

TABLE 29. COMPANY 5: KEY STRATERGIES

TABLE 30. COMPANY 6: KEY EXECUTIVES

TABLE 31. COMPANY 6: COMPANY SNAPSHOT

TABLE 32. COMPANY 6: OPERATING SEGMENTS

TABLE 33. COMPANY 6: PRODUCT PORTFOLIO

TABLE 34. COMPANY 6: KEY STRATERGIES

TABLE 35. COMPANY 7: KEY EXECUTIVES

TABLE 36. COMPANY 7: COMPANY SNAPSHOT

TABLE 37. COMPANY 7: OPERATING SEGMENTS

TABLE 38. COMPANY 7: PRODUCT PORTFOLIO

TABLE 39. COMPANY 7: KEY STRATERGIES

TABLE 40. COMPANY 8: KEY EXECUTIVES

TABLE 41. COMPANY 8: COMPANY SNAPSHOT

TABLE 42. COMPANY 8: OPERATING SEGMENTS

TABLE 43. COMPANY 8: PRODUCT PORTFOLIO

TABLE 44. COMPANY 8: KEY STRATERGIES

TABLE 45. COMPANY 9: KEY EXECUTIVES

TABLE 46. COMPANY 9: COMPANY SNAPSHOT

TABLE 47. COMPANY 9: OPERATING SEGMENTS

TABLE 48. COMPANY 9: PRODUCT PORTFOLIO

TABLE 49. COMPANY 9: KEY STRATERGIES

TABLE 50. COMPANY 10: KEY EXECUTIVES

TABLE 51. COMPANY 10: COMPANY SNAPSHOT

TABLE 52. COMPANY 10: OPERATING SEGMENTS

TABLE 53. COMPANY 10: PRODUCT PORTFOLIO

TABLE 54. COMPANY 10: KEY STRATERGIES LIST OF FIGURES

FIGURE 01. MEXICO RADIOPHARMACEUTICALS MARKET, 2022-2032

FIGURE 02. SEGMENTATION OF MEXICO RADIOPHARMACEUTICALS MARKET, 2022-2032

FIGURE 03. TOP INVESTMENT POCKETS IN MEXICO RADIOPHARMACEUTICALS MARKET (2023-2032)

FIGURE 04. PORTER FIVE-1

FIGURE 05. PORTER FIVE-2

FIGURE 06. PORTER FIVE-3

FIGURE 07. PORTER FIVE-4

FIGURE 08. PORTER FIVE-5

FIGURE 09. DRIVERS, RESTRAINTS AND OPPORTUNITIES: MEXICO RADIOPHARMACEUTICALS MARKET

FIGURE 10. MEXICO RADIOPHARMACEUTICALS MARKET,BY RADIOISOTOPE, 2022 ($MILLION)

FIGURE 11. MEXICO RADIOPHARMACEUTICALS MARKET,BY APPLICATION, 2022 ($MILLION)

FIGURE 12. MEXICO RADIOPHARMACEUTICALS MARKET,BY TYPE, 2022 ($MILLION)

FIGURE 13. MEXICO RADIOPHARMACEUTICALS MARKET,BY END USER, 2022 ($MILLION)

FIGURE 14. TOP WINNING STRATEGIES, BY YEAR

FIGURE 15. TOP WINNING STRATEGIES, BY DEVELOPMENT

FIGURE 16. TOP WINNING STRATEGIES, BY COMPANY

FIGURE 17. PRODUCT MAPPING OF TOP 10 PLAYERS

FIGURE 18. COMPETITIVE DASHBOARD

FIGURE 19. COMPETITIVE HEATMAP: MEXICO RADIOPHARMACEUTICALS MARKET

FIGURE 20. TOP PLAYER POSITIONING, 2022

FIGURE 21. COMPANY 1: NET SALES, 2020-2022* ($MILLION)

FIGURE 22. COMPANY 1: REVENUE SHARE, BY SEGMENT, 2022 (%)

FIGURE 23. COMPANY 1: REVENUE SHARE, BY GEOGRAPHY, 2022 (%)

FIGURE 24. COMPANY 2: NET SALES, 2020-2022* ($MILLION)

FIGURE 25. COMPANY 2: REVENUE SHARE, BY SEGMENT, 2022 (%)

FIGURE 26. COMPANY 2: REVENUE SHARE, BY GEOGRAPHY, 2022 (%)

FIGURE 27. COMPANY 3: NET SALES, 2020-2022* ($MILLION)

FIGURE 28. COMPANY 3: REVENUE SHARE, BY SEGMENT, 2022 (%)

FIGURE 29. COMPANY 3: REVENUE SHARE, BY GEOGRAPHY, 2022 (%)

FIGURE 30. COMPANY 4: NET SALES, 2020-2022* ($MILLION)

FIGURE 31. COMPANY 4: REVENUE SHARE, BY SEGMENT, 2022 (%)

FIGURE 32. COMPANY 4: REVENUE SHARE, BY GEOGRAPHY, 2022 (%)

FIGURE 33. COMPANY 5: NET SALES, 2020-2022* ($MILLION)

FIGURE 34. COMPANY 5: REVENUE SHARE, BY SEGMENT, 2022 (%)

FIGURE 35. COMPANY 5: REVENUE SHARE, BY GEOGRAPHY, 2022 (%)

FIGURE 36. COMPANY 6: NET SALES, 2020-2022* ($MILLION)

FIGURE 37. COMPANY 6: REVENUE SHARE, BY SEGMENT, 2022 (%)

FIGURE 38. COMPANY 6: REVENUE SHARE, BY GEOGRAPHY, 2022 (%)

FIGURE 39. COMPANY 7: NET SALES, 2020-2022* ($MILLION)

FIGURE 40. COMPANY 7: REVENUE SHARE, BY SEGMENT, 2022 (%)

FIGURE 41. COMPANY 7: REVENUE SHARE, BY GEOGRAPHY, 2022 (%)

FIGURE 42. COMPANY 8: NET SALES, 2020-2022* ($MILLION)

FIGURE 43. COMPANY 8: REVENUE SHARE, BY SEGMENT, 2022 (%)

FIGURE 44. COMPANY 8: REVENUE SHARE, BY GEOGRAPHY, 2022 (%)

FIGURE 45. COMPANY 9: NET SALES, 2020-2022* ($MILLION)

FIGURE 46. COMPANY 9: REVENUE SHARE, BY SEGMENT, 2022 (%)

FIGURE 47. COMPANY 9: REVENUE SHARE, BY GEOGRAPHY, 2022 (%)

FIGURE 48. COMPANY 10: NET SALES, 2020-2022* ($MILLION)

FIGURE 49. COMPANY 10: REVENUE SHARE, BY SEGMENT, 2022 (%)

FIGURE 50. COMPANY 10: REVENUE SHARE, BY GEOGRAPHY, 2022 (%

SELECT A FORMAT

Added to Cart

Single User

Electronic

$3570

Single User License

Multi User

Electronic

$4560

Multi User License

Enterprise License

Electronic

$5550

Enterprise License

Data Pack

Electronic

$2670

Data Pack License

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

SIMILAR REPORTS

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions